Aratana Introduces ENTYCE® (capromorelin oral solution) at ACVIM 2016

At the Intersection of Human Science and Veterinary Medicine, Aratana Therapeutics is continuing its mission of bringing new therapeutics to help raise the standard of care for pets.

Thank you to everyone we met at the 2016 American College of Veterinary Internal Medicine (ACVIM) Forum in Denver. It was our great pleasure to introduce you to ENTYCE® and explain how this new way to stimulate appetite in dogs may help improve the quality of life for your patients.

ENTYCE is the first FDA-approved therapeutic specifically designed to stimulate appetite in dogs and has the potential to transform the way you manage the symptom of inappetence. ENTYCE provides a safe and simple way to stimulate appetite, allowing you to focus on diagnosing and treating the underlying cause of the pet’s inappetence.

There was a great group of veterinarians at our breakfast session “Inappetence in Dogs: What’s New in its Management?” who had the opportunity to listen in as the latest research regarding appetite stimulation was presented by Jessica Wofford, DVM, PhD, Aratana Therapeutics.

We heard from a number of clinicians about limitations in using drugs extra-label without data to support their use. And we’re excited to present how ENTYCE is now an option to safely and effectively stimulate dogs’ appetites.

ENTYCE mimics ghrelin, the naturally occurring “hunger hormone” by binding to receptors and affecting signaling in the hypothalamus to cause appetite stimulation. It is estimated that inappetence affects more than 10 million dogs annually in the United States. Treatment with ENTYCE has been shown to safely and effectively stimulate appetite in client-owned dogs and increase food consumption in laboratory dogs.

If you weren’t able to attend the presentation, the slides are available in the Aratana Investor Room. You can also watch the ENTYCE mechanism of action video for a better understanding of how the therapeutic helps to increase appetite in dogs.

 

 

ENTYCE will be available in 10 mL, 15 mL and 30 mL bottles with a dosing syringe and intends to commercially launch in conjunction with the North American Veterinary Conference in February 2017.  View additional studies and information from Aratana relating to inappetence.

 

IMPORTANT SAFETY INFORMATION
ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information.

ENTYCE is a registered trademark of Aratana Therapeutics, Inc.

Recent News Posts

View All